← Insulet overview

Insulet vs Abbott Laboratories: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Insulet Corporation (PODD)

Q3 2026
▲2▼2

Insulet's innovation advances but safety, legal, and growth risks mount

  • Next-gen Omnipod 6 and type 2 system show strong trial results Insulet's next-generation Omnipod 6 and a closed-loop system for type 2 diabetes delivered strong trial results, signaling a promising product pipeline that could drive future growth.

    Highlights a key positive development that could support future revenue.

  • Omnipod 5 maintains rapid growth Omnipod 5 continued its rapid growth with 33% revenue growth and a 25% larger customer base, demonstrating strong demand for the current flagship product.

    Shows ongoing strong performance of the core product.

  • FDA Class I recall raises safety and regulatory concerns The FDA classified a recall of certain Omnipod devices as Class I due to a cannula tear causing insulin under-delivery, raising serious safety and regulatory concerns that could harm reputation and sales.

    A major regulatory setback with potential financial and reputational impact.

  • Guidance cut and downgrade on slowing growth and competition Insulet cut 2026 revenue growth guidance to 20-22% on weak U.S. Type 2 retention, and JPMorgan downgraded the stock to Neutral, slashing its price target to $152 from $275, citing slowing growth, rising attrition, and competition.

    Directly impacts investor expectations and stock valuation.

July 2026
▲2▼2

Insulet's innovation advances but safety, legal, and growth risks mount

  • Next-gen Omnipod 6 and type 2 system show strong trial results Insulet's next-generation Omnipod 6 and a closed-loop system for type 2 diabetes delivered strong trial results, signaling a promising product pipeline that could drive future growth.

    Highlights a key positive development that could support future revenue.

  • Omnipod 5 maintains rapid growth Omnipod 5 continued its rapid growth with 33% revenue growth and a 25% larger customer base, demonstrating strong demand for the current flagship product.

    Shows ongoing strong performance of the core product.

  • FDA Class I recall raises safety and regulatory concerns The FDA classified a recall of certain Omnipod devices as Class I due to a cannula tear causing insulin under-delivery, raising serious safety and regulatory concerns that could harm reputation and sales.

    A major regulatory setback with potential financial and reputational impact.

  • Guidance cut and downgrade on slowing growth and competition Insulet cut 2026 revenue growth guidance to 20-22% on weak U.S. Type 2 retention, and JPMorgan downgraded the stock to Neutral, slashing its price target to $152 from $275, citing slowing growth, rising attrition, and competition.

    Directly impacts investor expectations and stock valuation.

Latest
▼3

Insulet's U.S. Type 2 Weakness and Legal Woes Weigh on Outlook

  • Securities fraud class action expands with multiple law firm filings Several law firms filed or reminded investors of a securities fraud class action alleging Insulet misled about Omnipod safety and manufacturing. The August 31 lead plaintiff deadline keeps legal risk in focus, which can pressure the stock as investors weigh potential costs and reputational damage.

    This is a new legal development that adds to regulatory risk and could hurt investor confidence.

  • Insulet cuts 2026 revenue growth guidance on weak U.S. Type 2 retention Insulet lowered its 2026 revenue growth outlook to 20-22% from a prior forecast, citing lower-than-expected use and retention among U.S. Type 2 diabetes customers. Although Q2 revenue beat estimates, the reduced guidance signals weaker future demand, which pushes the stock down.

    This is a new guidance cut that directly reduces expected future revenue and earnings.

  • JPMorgan downgrades Insulet to Neutral, slashes price target to $152 JPMorgan downgraded Insulet to Neutral from Overweight and cut its price target to $152 from $275, citing slowing U.S. growth, rising Type 2 attrition, and competition. The downgrade reflects a more cautious view on 2027, which can lead to selling pressure and lower valuation.

    This is a new analyst downgrade that directly impacts investor sentiment and valuation.

▼2▲1

Insulet's strong sales offset by FDA Class I recall and fraud lawsuit

  • Next-gen Omnipod 6 shows strong trial results Insulet reported positive clinical trial results for its next-generation Omnipod 6 automated insulin delivery system and a fully closed-loop system for type 2 diabetes. The trial showed up to 50% more automated insulin delivery and fewer manual boluses. This innovation could drive future demand and support long-term growth, pushing the stock up.

    New product pipeline news that could boost future revenue and investor confidence.

  • FDA Class I recall of Omnipod devices The FDA classified a recall of certain Omnipod 5, DASH, and Eros insulin pumps as Class I, the most serious type, due to a cannula tear that can cause insulin leakage and under-delivery. This raises safety concerns, may lead to regulatory scrutiny, and could hurt sales and reputation, pushing the stock down.

    A major regulatory setback that directly threatens patient safety and future revenue.

  • Securities fraud class action lawsuit filed A securities fraud class action lawsuit alleges Insulet misled investors about product safety and manufacturing quality. The lawsuit follows two product corrections in 2026 that caused stock drops. Legal costs and potential damages could weigh on the stock, and the lawsuit may keep investors cautious.

    New legal risk that could result in financial penalties and further erode investor trust.

  • Strong Omnipod 5 momentum vs. competition and macro headwinds Omnipod 5 continues to grow rapidly, with 33% revenue growth and a 25% larger customer base. However, intensifying competition and higher raw material and shipping costs from the Middle East conflict could limit profit margins. The strong demand supports the stock, but these headwinds may cap gains.

    Balances the positive sales momentum against real pressures that could affect profitability.

Abbott Laboratories (ABT)

Q3 2026
▲3▼1

Abbott's Q3: Strong Results, New Products, But Exact Sciences Deal Weighs

  • Record Q2 sales and raised guidance Abbott reported record second-quarter sales of $12.6 billion, beating expectations, and raised its earnings guidance for the year. Growth was broad, led by Diagnostics (up 42.3%) and Medical Devices (up 9%).

    This shows the company's core business performed better than expected, which likely boosted investor confidence.

  • New product approvals and launches Abbott won FDA approval for Freenome's colorectal cancer blood test, launched Libre Duo (the first glucose-ketone sensor), and received heart-device approvals. It also partnered with Google Health to advance digital health.

    These new products expand Abbott's offerings and open new revenue streams, driving future growth potential.

  • Cash returned to shareholders Abbott paid its 411th consecutive quarterly dividend and repurchased $1.35 billion of its own stock. This signals financial strength and a commitment to returning cash to shareholders.

    Returning cash supports the stock price by rewarding investors and showing confidence in the business.

  • Exact Sciences acquisition and lingering litigation The $21 billion Exact Sciences deal diluted earnings guidance and increased interest expense. NEC litigation settled for $670 million, but about 1,700 lawsuits remain, and the Sturgis formula recall cost $385 million to resolve.

    These costs and legal uncertainties weigh on profitability and investor sentiment, acting as a counterweight to the positive news.

August 2026
▲3

Abbott advances partnerships, launches, and buybacks; NEC settlement leaves some risk

  • Google Health partnership and MiniMed sensor supply Abbott partnered with Google Health to embed Lingo glucose data into its app and will supply its Instinct sensor for MiniMed's insulin pump, expanding its diabetes ecosystem and opening new revenue channels.

    These partnerships are new strategic moves that could drive future growth and were not in earlier reports.

  • Accelerating medical devices growth and new product launches Medical devices growth accelerated, led by electrophysiology and continuous glucose monitoring (CGM), which has a long runway below its 75–80 million potential users. New launches include Similac whole milk formula, SimpleScreen CRC test, Ensure Max Protein, and CardioMEMS updates.

    This highlights the core growth engine and pipeline expansion that are new developments in the period.

  • Capital returns: 411th consecutive dividend and $1.35 billion buyback Abbott declared its 411th consecutive quarterly dividend and completed a $1.35 billion share buyback, returning cash to shareholders and signaling confidence in its financial position.

    These capital actions are new and reflect management's commitment to shareholder returns.

  • NEC litigation settled for $670 million, but ~1,700 lawsuits remain The NEC litigation settled for $670 million, removing a major overhang, but roughly 1,700 lawsuits are still outstanding, leaving legal uncertainty that could weigh on the stock.

    This is a new development that partially resolves a known risk but leaves residual uncertainty.

Latest
▲4

New product launches and partnerships build Abbott's growth story

  • New product launches expand Abbott's portfolio Abbott launched several new products: Similac whole milk formula, SimpleScreen CRC blood test, Ensure Max Protein powder, and CardioMEMS updates. These launches open new revenue streams and strengthen Abbott's competitive position, supporting higher sales and stock price over time.

    Multiple new product launches are a key driver of future growth and investor optimism.

  • Lingo partnership with Berry Street adds service layer Abbott's Lingo glucose monitor is now paired with Berry Street's dietitian coaching in an exclusive US deal. This adds a recurring service layer and discounted access, which could boost Lingo adoption and create a new revenue stream beyond hardware sales.

    The partnership enhances the value proposition of Lingo and may accelerate user growth.

  • Volt PFA system expands into Canada Abbott's Volt Pulsed Field Ablation System was used for the first time in Canada after Health Canada authorization. This expands Abbott's electrophysiology footprint and validates its technology, potentially driving procedure growth and market share gains in a large AFib market.

    Geographic expansion of a key device platform signals growing adoption and revenue potential.

  • Dividend increase and buyback support shareholder returns Abbott declared its 411th consecutive quarterly dividend and completed a $1.35 billion share buyback. These actions return cash to shareholders, signal confidence, and can support the stock price by reducing shares outstanding and attracting income-focused investors.

    Capital return programs are a direct positive for shareholder value and stock support.

September 2026
▲4

Abbott's legal clouds clear as new heart and diabetes devices win approvals

  • FDA clears first dual glucose-ketone sensor Abbott won FDA authorization for Libre Duo 10 Day, the first biowearable that tracks both glucose and ketones, with a U.S. launch planned for later this year. A genuinely new product with no direct rival strengthens Abbott's fast-growing diabetes sensor business and supports a higher stock price.

    A first-of-its-kind product approval is a real new growth driver, not a repeat of earlier news.

  • Two new heart-device approvals widen Abbott's lead Abbott received CE Mark for the Amulet 360 stroke-prevention device and FDA approval for the TactiFlex Duo ablation catheter, its fourth and fifth heart-rhythm approvals in about a year. More approved tools mean more procedures and recurring sales, pushing the stock up.

    These are new regulatory wins that expand Abbott's electrophysiology lineup and revenue runway.

  • Infant formula legal overhang largely resolved Abbott agreed to pay $385 million to settle Department of Justice and state claims over its 2022 Sturgis formula recall, with no finding of fault and the criminal probe closed. Removing this legal cloud lets investors focus on the core business, lifting the stock.

    This is a new settlement that clears a major legal risk, a direct positive for the share price.

  • Citi sees Abbott taking heart-device share from Boston Scientific Citi downgraded rival Boston Scientific, saying it will lose market share in left atrial appendage closure when Abbott's Amulet device launches in 2027. That independent view of Abbott as the winner in a growing market supports the stock.

    A fresh analyst call frames Abbott as a competitive gainer, a new reason for optimism.

▲4

Abbott's legal clouds clear as new heart and diabetes devices win approvals

  • FDA clears first dual glucose-ketone sensor Abbott won FDA authorization for Libre Duo 10 Day, the first biowearable that tracks both glucose and ketones, with a U.S. launch planned for later this year. A genuinely new product with no direct rival strengthens Abbott's fast-growing diabetes sensor business and supports a higher stock price.

    A first-of-its-kind product approval is a real new growth driver, not a repeat of earlier news.

  • Two new heart-device approvals widen Abbott's lead Abbott received CE Mark for the Amulet 360 stroke-prevention device and FDA approval for the TactiFlex Duo ablation catheter, its fourth and fifth heart-rhythm approvals in about a year. More approved tools mean more procedures and recurring sales, pushing the stock up.

    These are new regulatory wins that expand Abbott's electrophysiology lineup and revenue runway.

  • Infant formula legal overhang largely resolved Abbott agreed to pay $385 million to settle Department of Justice and state claims over its 2022 Sturgis formula recall, with no finding of fault and the criminal probe closed. Removing this legal cloud lets investors focus on the core business, lifting the stock.

    This is a new settlement that clears a major legal risk, a direct positive for the share price.

  • Citi sees Abbott taking heart-device share from Boston Scientific Citi downgraded rival Boston Scientific, saying it will lose market share in left atrial appendage closure when Abbott's Amulet device launches in 2027. That independent view of Abbott as the winner in a growing market supports the stock.

    A fresh analyst call frames Abbott as a competitive gainer, a new reason for optimism.

▲3▼1

Abbott's core growth accelerates as Google deal and NEC settlement reshape outlook

  • Google Health partnership expands Lingo reach Abbott and Google launched a multi-year partnership to embed Lingo glucose data into the Google Health app, pairing it with AI coaching. This could drive adoption of Abbott's biowearable and open a new consumer health channel, supporting the stock.

    New partnership is a fresh growth catalyst for Abbott's diabetes care business.

  • Instinct sensor powers MiniMed's new insulin pump Abbott is supplying its Instinct sensor for MiniMed's app-controlled insulin pump in the U.S. This broadens Abbott's role in diabetes devices and adds recurring sensor revenue, a positive for the stock.

    New product integration expands Abbott's diabetes device footprint.

  • Medical devices growth driven by electrophysiology and CGM Abbott's medical devices arm is accelerating, with the Volt PFA catheter launching fully and CGM adoption far below its 75-80 million potential users. This long runway supports future revenue growth and a higher stock price.

    Highlights durable growth drivers in Abbott's largest device segments.

  • NEC litigation settled for $670 million, but 1,700 cases remain Abbott agreed to pay about $670 million to settle the Gill case and roughly 2,000 NEC claims, without admitting liability. While this removes a major overhang, about 1,700 lawsuits remain, keeping some legal uncertainty on the stock.

    Settlement is a major legal development that reduces but does not eliminate litigation risk.

July 2026
▲3▼1

Abbott beats Q2, raises guidance, but Exact Sciences costs and NEC litigation weigh

  • Q2 earnings beat and raised guidance Abbott reported record Q2 sales of $12.6 billion, up 13%, and adjusted EPS of $1.31, beating expectations. Management raised full-year EPS guidance to $5.45–$5.60, sending the stock up over 10% initially.

    This is the main new event that drove the stock in July.

  • Medical Devices and Diagnostics growth Medical Devices grew 9%, while Diagnostics surged 42.3% due to the Exact Sciences acquisition. Nutrition trends also improved, showing broad-based strength across Abbott's businesses.

    These segment results explain the strong revenue beat and support the positive reaction.

  • FDA approval of Freenome CRC blood test The FDA approved Freenome's colorectal cancer blood test, which Abbott will exclusively commercialize in the U.S. This adds a new revenue stream and expands Abbott's diagnostic offerings.

    This is a new product approval that could drive future growth.

  • Exact Sciences costs and NEC litigation The $21 billion Exact Sciences deal diluted guidance and spiked interest expense from $50 million to $299 million. Ongoing NEC litigation uncertainty continues to weigh on investor sentiment, keeping a lid on the stock.

    These are the main counterweights that prevented even stronger gains.

▲2▼2

Abbott's Q2 beat and raised guidance offset by Exact Sciences dilution and NEC litigation

  • Q2 beat and raised guidance Abbott reported record Q2 sales of $12.6 billion, up 13%, and adjusted EPS of $1.31, beating estimates. Management raised full-year adjusted EPS guidance to $5.45–$5.60. This shows the core business is strong and supports a higher stock price.

    This is the main positive driver this period, directly boosting investor confidence and the stock's valuation.

  • FDA approves Freenome CRC blood test, Abbott to commercialize The FDA approved Freenome's SimpleScreen CRC blood test, and Abbott will exclusively sell it in the U.S. starting this fall. This expands Abbott's cancer diagnostics portfolio and adds a new revenue stream, pushing the stock up.

    This is a new product approval that directly expands Abbott's diagnostics business and future sales.

  • Exact Sciences acquisition dilutes guidance and raises interest expense Abbott's $21 billion Exact Sciences acquisition added $919 million in Cologuard sales but also caused interest expense to jump from $50 million to $299 million and diluted full-year guidance. This weighs on the stock as investors worry about the cost of the deal.

    This is a key counterweight explaining why the stock hasn't risen more despite strong results.

  • Ongoing NEC litigation uncertainty Uncertainty around NEC litigation related to Abbott's preterm infant formula continues to weigh on investor sentiment. This legal risk keeps a lid on the stock price, as investors await clarity on potential liabilities.

    This is a persistent negative factor that offsets positive business momentum.

▲3

Abbott beats Q2, raises guidance, stock jumps 11%

  • Q2 beat and raised full-year guidance Abbott reported Q2 adjusted EPS of $1.31, beating estimates, with sales up 13% to $12.59 billion. Management raised full-year adjusted EPS guidance to $5.45–$5.60 and reaffirmed comparable sales growth of 6.5–7.5%. The stock jumped over 10% as results eased worries about medical devices and nutrition.

    This is the main new event that directly drove the stock's sharp move this period.

  • Medical Devices and Diagnostics strength Medical Devices sales grew 9% to $5.85 billion, led by electrophysiology and diabetes care. Diagnostics surged 42.3% to $3.09 billion after the Exact Sciences acquisition, with cancer diagnostics growing double digits. This shows the core businesses are performing well and supports future growth.

    It explains which parts of the business are driving the beat and future optimism.

  • Nutrition and other segments improving Nutrition sales declined 3.1% but rose sequentially by $125 million, and management expects about 80% of the second-half lift from Nutrition, Electrophysiology, Core Laboratory, and Cancer Diagnostics. Established Pharmaceuticals grew 8.4%. This signals a turnaround in previously weak areas.

    It shows the company is addressing prior weaknesses, which supports the raised guidance.

Q2 2026
▲4

Abbott's legal cloud lifts, dividend grows, and new products drive optimism

  • DOJ ends criminal probe into baby formula plant The U.S. Justice Department closed its criminal investigation into Abbott's Michigan baby formula plant, opting for civil penalties instead. This removes a major legal risk that had been hanging over the company, making the stock more attractive to investors.

    This is a new development that directly reduces regulatory uncertainty and boosts investor confidence.

  • Abbott raises dividend for 54th straight year Abbott increased its dividend for the 54th consecutive year, with a quarterly payout of $0.740243 per share, yielding 2.76%. This signals financial strength and a commitment to returning cash to shareholders, which can support the stock price.

    This is a new event that highlights Abbott's financial health and shareholder returns.

  • New Alzheimer's blood test licensing deal ALZpath licensed its pTau217 antibody to Abbott for a blood-based Alzheimer's test on Abbott's Alinity systems. This expands Abbott's diagnostic portfolio into a large, growing market, potentially adding new revenue streams.

    This is a new partnership that opens a new market opportunity for Abbott.

  • FreeStyle Libre expansion into Type 2 basal insulin market Abbott's FreeStyle Libre continuous glucose monitor is expanding into the large Type 2 basal-insulin market, with trial data showing improved outcomes. This could significantly increase the addressable market and drive future sales growth.

    This is a new catalyst that could accelerate growth in Abbott's diabetes care business.

June 2026
▲4

Abbott's legal cloud lifts, dividend grows, and new products drive optimism

  • DOJ ends criminal probe into baby formula plant The U.S. Justice Department closed its criminal investigation into Abbott's Michigan baby formula plant, opting for civil penalties instead. This removes a major legal risk that had been hanging over the company, making the stock more attractive to investors.

    This is a new development that directly reduces regulatory uncertainty and boosts investor confidence.

  • Abbott raises dividend for 54th straight year Abbott increased its dividend for the 54th consecutive year, with a quarterly payout of $0.740243 per share, yielding 2.76%. This signals financial strength and a commitment to returning cash to shareholders, which can support the stock price.

    This is a new event that highlights Abbott's financial health and shareholder returns.

  • New Alzheimer's blood test licensing deal ALZpath licensed its pTau217 antibody to Abbott for a blood-based Alzheimer's test on Abbott's Alinity systems. This expands Abbott's diagnostic portfolio into a large, growing market, potentially adding new revenue streams.

    This is a new partnership that opens a new market opportunity for Abbott.

  • FreeStyle Libre expansion into Type 2 basal insulin market Abbott's FreeStyle Libre continuous glucose monitor is expanding into the large Type 2 basal-insulin market, with trial data showing improved outcomes. This could significantly increase the addressable market and drive future sales growth.

    This is a new catalyst that could accelerate growth in Abbott's diabetes care business.

▲4

Abbott's legal cloud lifts, dividend grows, and new products drive optimism

  • DOJ ends criminal probe into baby formula plant The U.S. Justice Department closed its criminal investigation into Abbott's Michigan baby formula plant, opting for civil penalties instead. This removes a major legal risk that had been hanging over the company, making the stock more attractive to investors.

    This is a new development that directly reduces regulatory uncertainty and boosts investor confidence.

  • Abbott raises dividend for 54th straight year Abbott increased its dividend for the 54th consecutive year, with a quarterly payout of $0.740243 per share, yielding 2.76%. This signals financial strength and a commitment to returning cash to shareholders, which can support the stock price.

    This is a new event that highlights Abbott's financial health and shareholder returns.

  • New Alzheimer's blood test licensing deal ALZpath licensed its pTau217 antibody to Abbott for a blood-based Alzheimer's test on Abbott's Alinity systems. This expands Abbott's diagnostic portfolio into a large, growing market, potentially adding new revenue streams.

    This is a new partnership that opens a new market opportunity for Abbott.

  • FreeStyle Libre expansion into Type 2 basal insulin market Abbott's FreeStyle Libre continuous glucose monitor is expanding into the large Type 2 basal-insulin market, with trial data showing improved outcomes. This could significantly increase the addressable market and drive future sales growth.

    This is a new catalyst that could accelerate growth in Abbott's diabetes care business.